Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Short Interest Update

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 8,080,000 shares, a growth of 64.9% from the February 29th total of 4,900,000 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is presently 4.5 days.

Institutional Trading of Tandem Diabetes Care

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. raised its holdings in Tandem Diabetes Care by 79.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,788 shares of the medical device company's stock worth $171,000 after purchasing an additional 2,562 shares during the last quarter. Kingdon Capital Management L.L.C. acquired a new position in shares of Tandem Diabetes Care during the 4th quarter worth about $5,744,000. Vanguard Group Inc. grew its position in shares of Tandem Diabetes Care by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company's stock worth $207,708,000 after buying an additional 18,571 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Tandem Diabetes Care by 5.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 36,747 shares of the medical device company's stock worth $1,087,000 after buying an additional 1,931 shares during the period. Finally, Public Employees Retirement System of Ohio grew its position in shares of Tandem Diabetes Care by 50.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 39,530 shares of the medical device company's stock worth $1,169,000 after buying an additional 13,287 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Stifel Nicolaus upgraded shares of Tandem Diabetes Care from a "hold" rating to a "buy" rating and boosted their target price for the company from $24.00 to $37.00 in a research note on Tuesday. StockNews.com raised Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Thursday, March 21st. Finally, Citigroup lifted their price target on Tandem Diabetes Care from $25.00 to $31.00 and gave the company a "neutral" rating in a report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $36.36.

Tandem Diabetes Care Trading Up 0.3 %

NASDAQ:TNDM traded up $0.11 on Friday, hitting $35.41. 1,809,821 shares of the stock were exchanged, compared to its average volume of 2,391,823. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of -10.29 and a beta of 1.08. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $43.51. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The company's 50-day moving average price is $26.97 and its 200 day moving average price is $23.67.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. On average, equities research analysts forecast that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.